- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03104673
Molecular Signature Children (MSP_Ext)
Molecular Signature of Karen and Burmese Children Until Two Years of Age on the Thailand--Myanmar Border: a Study Extension of TMEC 15-062
Preterm birth (PTB) occurs before 37 weeks of gestation and is a major cause of neonatal mortality and morbidity. PTB results from heterogeneous influences. One of them is the inherited predisposition of spontaneous PTB, and another is the change in the placental microbial composition as this can cause infections, which lead to inflammation, a common cause of preterm birth. Interestingly, maternal periodontal disease is an independent risk factor for PTB, low birth weight and fetal growth restriction. Immune responses to infectious events or inflammation as well as genetic predisposition to inherited conditions have successfully been studied by using assessing genetic expression profiling. The molecular signature is sets of genes, proteins, genetic variants or other variables that can be used as markers for a particular phenotype.
Child morbidity from malnutrition resulting in poor growth and stunting remains a major public health issue that affects the local population just like PTB. While risk factors for malnutrition are multifaceted, there is also a hypothesized causal link between early gut microbiome disruption that leads to chronic malnutrition in otherwise healthy infants.
Molecular signatures including the intestinal microbiome development of preterm infants will be evaluated and compared to the term (≥37 weeks' gestation) counterparts. Moreover, a comprehensive examination of possible factors associated with poor growth and poor motor- and neurodevelopment will be assessed.
In this extension study: The primary goal for the child is to evaluate the perturbation in the development of the genomic profile including intestinal microbial habitat from children in a rural and limited-resource setting from birth to two years of life.
Study Overview
Status
Conditions
Detailed Description
Rationale:
The importance of early life epigenetics is now recognized to have direct implications for health in later life and a consistent limitation expressed in peer reviewed publications has been the small sample size of the studies. Rather than establish a separate cohort to study epigenetics in young children in this environment this extension study of TMEC 15-062 (Molecular signature of Karen and Burmese women on the Thailand--Myanmar border) aims to build on the detailed sampling of the mothers to not only identify biomarkers of preterm labor but also to understand high rates of stunting and anaemia in this area, and possibly develop predictive tools or pave new ways for prevention in the future.
Moreover, a non-invasive intervention in the form of nutrition and WASH counselling may provide information on whether this form of engagement can positively influence child development, prevent malnutrition and whether perturbations in the infants molecular signature can be observed.
In addition, the mothers exposed to the sampling procedure at birth in this study will be able to make a well-informed decision about whether they wish to enrol the child in such a study.
The rationale for the planned samples in children born to mothers who participated in the TMEC 15-062 study are summarized in the following text:
Child gut microbiome and assessment of nutrition from stool samples (Risk-none) The intestinal ecosystem is very dynamic, especially in the first period of life, as it needs to evolve from scratch, hence investigators want to follow children and analyse stool samples in first 24 month of life. investigators propose to assess what kind of impact the gut microbiome has on the child's growth and development. Since exposure to helminths is common in the study population, children stool samples will also be used to examine for helminthic infestations.
This point would also include a home visit as part of nutrition evaluation by questionnaire and direct observation (food preparation including hygiene, child food content, feeding patterns) to relate to microbiome.
Early childhood Transcriptome from capillary blood (Risk-minimum) This point will enable us to understand whether preterm infants have different gene expression than their term counterparts and if so, how it evolves in the early period of life. Moreover, specific signals for children at risk for or suffering from malnutrition or stunting resulting from gastrointestinal inflammation or barrier disruption could be picked up. Total blood 0.85 mL in 2 years.
Early childhood detection of anaemia from capillary blood (Risk-minimum) Anaemia will be treated and iron supplement effect on gut microbiome analysed. Total blood 0.85 mL in 2 years.
Early childhood detection of soil transmitted helminth infection from stool sample (Risk-none) Helminth infection will be treated and the effect on gut microbiome analysed. Stool sample each visit.
Child growth assessment and evaluation of motor and neurocognitive development (Risk-none) Premature infants have a higher risk for lifelong health and development problems. Investigators propose to follow the children's over the period of 2 years to assess their growth and their neurocognitive and motor development. Preterm children's growth and development will be compared to term neonates. The recommended schedule of growth assessment in healthy children is (1, 2, 4, 6, 9, 12, 18, 24 months). In this study children will be followed more frequently: monthly in the first year of life and 3 monthly in the 2nd year of life (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24 months). The reasons for this include: the objective of the root study TMEC 15-062 which is on preterm infants who require closer follow up, to relate perturbations of biomarkers to stunting, and in this mobile population scheduled visits may be missed so a more flexible arrangement for checking anthropometry at any monthly visit in the first year of life reduces the chance that poor growth is not identified.
In addition, the growth and development of children born to mothers who had a febrile episode during pregnancy will be compared to children whose mothers did not experience fever episodes during pregnancy.
Children with poor growth or malnutrition will be given supplementary nutrition and nutrition advice will be given to the mother.
Grant reference number: B9R01250
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Mae Sot
-
Tak, Mae Sot, Thailand, 63110
- Shoklo Malaria Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Karen or Burmese pregnant woman in study TMEC 15-062 who are willing to have their offspring (children) comply with all study requirements
- Pregnant woman is willing and able to give informed consent for her child to participate in this study
Exclusion Criteria:
- Children (in the investigators opinion) with any social or physical condition which would make it difficult to comply with study requirements
Inclusion Criteria for water, sanitation and hygiene (WASH) radomization
- Mother enrolled to MSP (TMEC 15-062) and child enrolled in MSP_Ext (TMEC 17-008)
- Term pregnancy (gestational age ≥37 weeks)
- Clinic birth
- Normal new-born
- Post-partum mother willing to have home visits
- Post-partum mother willing and able to give informed consent to participate in this study
Exclusion Criteria for water, sanitation and hygiene (WASH) randomization
- Lives too far to make home visits feasible
- Home situation unstable and likely to move before the child is 9 months old
- Social situation that would make it difficult for the mother to comply
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of the molecular signature of child
Time Frame: at birth
|
Early childhood Transcriptome from capillary blood
|
at birth
|
Characterization of the molecular signature of child
Time Frame: 1 year
|
Early childhood Transcriptome from capillary blood
|
1 year
|
Characterization of the molecular signature of child
Time Frame: 2 years
|
Early childhood Transcriptome from capillary blood
|
2 years
|
Proportions of nutrition and water, sanitation and hygiene (WASH) behaviours in home-based compared to clinic-based care
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of children with biomarkers perturbations associated with poor child growth
Time Frame: From birth to two years of life.
|
Describe the biomarkers predictive
|
From birth to two years of life.
|
Proportion of children with biomarkers perturbations associated with neurocognitive and motor development
Time Frame: From birth to two years of life.
|
Describe the biomarkers predictive
|
From birth to two years of life.
|
Proportion of children with biomarkers perturbations associated with anaemia
Time Frame: From birth to two years of life.
|
Describe the biomarkers predictive
|
From birth to two years of life.
|
Association between nutrition and water, sanitation and hygiene (WASH) behaviours and biomarker signature perturbations in children
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMRU1502 Ext
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Birth
-
e-Bio CorpRecruitingPreterm Labor | PreTerm Birth | Preterm Labor With Delivery NosUnited States
-
Thomas Jefferson UniversityCompleted
-
Chelsea and Westminster NHS Foundation TrustSPD Development Company Limited; Borne CharityRecruitingPreterm Birth | Preterm Labor | Preterm Birth Complication | Preterm Premature Rupture of Membrane | Preterm PregnancyUnited Kingdom
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Cairo UniversityCompleted
-
University of OklahomaCompletedPreTerm Birth | PreTerm NeonateUnited States
-
Federico II UniversityRecruiting
-
University of OxfordShoklo Malaria Research UnitCompleted
-
Eunice Kennedy Shriver National Institute of Child...CompletedPregnancy | Preterm Birth | Preterm LaborUnited States
-
University Hospital Inselspital, BerneAmniSure International LLCCompletedPreterm Birth | Preterm LabourSwitzerland